Role of the ubiquitin proteasome system in renal cell carcinoma

BMC Biochemistry

Volumn 8, Issue SUPPL. 1, 2007, Pages

  Corn, Paul G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; ERYTHROPOIETIN; IMIDAZOLINE DERIVATIVE; PROTEASOME; UBIQUITIN; VASCULOTROPIN; ENZYME INHIBITOR; UBIQUITIN PROTEIN LIGASE;

ANGIOGENESIS; BREAST CANCER; CARCINOGENESIS; CELL HYPOXIA; CHRONIC MYELOID LEUKEMIA; DNA REPAIR; DRUG INHIBITION; EMBRYO DEVELOPMENT; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; IN VITRO STUDY; KIDNEY CARCINOMA; METHYLATION; NONHUMAN; PROSTATE CANCER; PROTEIN INTERACTION; REVIEW; TUMOR SUPPRESSOR GENE; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; KIDNEY TUMOR; PHYSIOLOGY;

ANIMALS; CARCINOMA, RENAL CELL; ENZYME INHIBITORS; HUMANS; KIDNEY NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 38449084670     PISSN: None     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/1471-2091-8-S1-S4     Document Type: Review

References (106)

1. Renal-cell carcinoma. HT Cohen FJ McGovern, N Engl J Med 353 23 2477 90 2005 Dec 8 10.1056/NEJMra043172 16339096
2. Hereditary renal cancers. PL Choyke GM Glenn MM Walther B Zbar WM Linehan, Radiology 226 1 33 46 2003 Jan 10.1148/radiol.2261011296 12511666
3. Role of VHL gene mutation in human cancer. WY Kim WG Kaelin, J Clin Oncol 22 24 4991 5004 2004 Dec 15 10.1200/JCO.2004.05.061 15611513
4. Mutations of the VHL tumour suppressor gene in renal carcinoma. JR Gnarra K Tory Y Weng L Schmidt MH Wei H Li, Nat Genet 7 1 85 90 1994 May 10.1038/ng0594-85 7915601
5. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. T Shuin K Kondo S Torigoe T Kishida Y Kubota M Hosaka, Cancer Res 54 11 2852 5 1994 Jun 1 8187067
6. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. JM Whaley J Naglich L Gelbert YE Hsia JM Lamiell JS Green, Am J Hum Genet 55 6 1092 102 1994 Dec 7977367
7. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. C Gallou D Joly A Mejean F Staroz N Martin G Tarlet, Hum Mutat 1999 13 6 464 75 10.1002/(SICI)1098- 1004(1999)13:6<464::AID-HUMU6>3.0.CO;2-A 10408776
8. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. K Kondo M Yao M Yoshida T Kishida T Shuin T Miura, Genes Chromosomes Cancer 34 1 58 68 2002 May 10.1002/gcc.10054 11921283
9. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. JG Herman F Latif Y Weng MI Lerman B Zbar S Liu, Proc Natl Acad Sci U S A 91 21 9700 4 1994 Oct 11 7937876 10.1073/pnas.91.21.9700
10. Heredity and cancer in man. AG Knudson Jr LC Strong DE Anderson, Prog Med Genet 1973 9 113 58 4351406
11. Molecular basis of the VHL hereditary cancer syndrome. WG Kaelin Jr, Nat Rev Cancer 2 9 673 82 2002 Sep 10.1038/nrc885 12209156
12. The von Hippel-Lindau tumor suppressor gene and kidney cancer. WG Kaelin Jr, Clin Cancer Res 10 18 Pt 2 6290S 5S 2004 Sep 15 15448019
13. Identification of the von Hippel-Lindau disease tumor suppressor gene. F Latif K Tory J Gnarra M Yao FM Duh ML Orcutt, Science 260 5112 1317 20 1993 May 28 10.1126/science.8493574 8493574
14. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. O Iliopoulos AP Levy C Jiang WG Kaelin Jr MA Goldberg, Proc Natl Acad Sci U S A 93 20 10595 9 1996 Oct 1 8855223 10.1073/pnas.93.20.10595
15. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. PH Maxwell MS Wiesener GW Chang SC Clifford EC Vaux ME Cockman, Nature 399 6733 271 5 1999 May 20 10353251
16. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. LF Brown B Berse RW Jackman K Tognazzi EJ Manseau HF Dvorak, Am J Pathol 143 5 1255 62 1993 Nov 8238242
17. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. H Igarashi M Esumi H Ishida K Okada, Cancer 95 1 47 53 2002 Jul 1 10.1002/cncr.10635 12115316
18. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. JL Da Silva C Lacombe P Bruneval N Casadevall M Leporrier JP Camilleri, Blood 75 3 577 82 1990 Feb 1 2297568
19. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. CC Wykoff NJ Beasley PH Watson KJ Turner J Pastorek A Sibtain, Cancer Res 60 24 7075 83 2000 Dec 15 11156414
20. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. KM Lonergan O Iliopoulos M Ohh T Kamura RC Conaway JW Conaway, Mol Cell Biol 18 2 732 41 1998 Feb 9447969
21. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. J Lisztwan G Imbert C Wirbelauer M Gstaiger W Krek, Genes Dev 13 14 1822 33 1999 Jul 15 10421634
22. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. K Iwai K Yamanaka T Kamura N Minato RC Conaway JW Conaway, Proc Natl Acad Sci U S A 96 22 12436 41 1999 Oct 26 10535940 10.1073/pnas.96.22.12436
23. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. M Ivan K Kondo H Yang W Kim J Valiando M Ohh, Science 292 5516 464 8 2001 Apr 20 11292862
24. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. MH Glickman A Ciechanover, Physiol Rev 82 2 373 428 2002 Apr 11917093
25. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. AM Burger AK Seth, Eur J Cancer 40 15 2217 29 2004 Oct 10.1016/j.ejca.2004.07.006 15454246
26. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. D Hoeller CM Hecker I Dikic, Nat Rev Cancer 6 10 776 88 2006 Oct 10.1038/nrc1994 16990855
27. Narrative review: protein degradation and human diseases: the ubiquitin connection. E Reinstein A Ciechanover, Ann Intern Med 145 9 676 84 2006 Nov 7 17088581
28. CHIP: a link between the chaperone and proteasome systems. H McDonough C Patterson, Cell Stress Chaperones 2003 8 4 303 8 15115282 10.1379/1466- 1268(2003)008<0303:CALBTC>2.0.CO;2
29. Ubiquitin is the ATP-dependent proteolysis factor I of rabbit reticulocytes. KD Wilkinson MK Urban AL Haas, J Biol Chem 255 16 7529 32 1980 Aug 25 6249803
30. Molecular cloning, sequence, and tissue distribution of the human ubiquitin-activating enzyme E1. PM Handley M Mueckler NR Siegel A Ciechanover AL Schwartz, Proc Natl Acad Sci U S A 88 1 258 62 1991 Jan 1 1986373 10.1073/pnas.88.1.258
31. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. A Hershko H Heller S Elias A Ciechanover, J Biol Chem 258 13 8206 14 1983 Jul 10 6305978
32. The protein substrate binding site of the ubiquitin-protein ligase system. A Hershko H Heller E Eytan Y Reiss, J Biol Chem 261 26 11992 9 1986 Sep 15 3017957
33. Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. A Hershko A Ciechanover H Heller AL Haas IA Rose, Proc Natl Acad Sci U S A 77 4 1783 6 1980 Apr 6990414 10.1073/pnas.77.4.1783
34. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. V Chau JW Tobias A Bachmair D Marriott DJ Ecker DK Gonda, Science 243 4898 1576 83 1989 Mar 24 10.1126/science.2538923 2538923
35. Recognition of the polyubiquitin proteolytic signal. JS Thrower L Hoffman M Rechsteiner CM Pickart, EMBO J 19 1 94 102 2000 Jan 4 10619848 10.1093/emboj/19.1.94
36. Protein regulation by monoubiquitin. L Hicke, Nat Rev Mol Cell Biol 2 3 195 201 2001 Mar 10.1038/35056583 11265249
37. Distinct monoubiquitin signals in receptor endocytosis. K Haglund PP Di Fiore I Dikic, Trends Biochem Sci 28 11 598 603 2003 Nov 10.1016/j.tibs.2003.09. 005 14607090
38. Monoubiquitylation promotes mitochondrial p53 translocation. ND Marchenko S Wolff S Erster K Becker UM Moll, EMBO J 2007 Feb 1
39. Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. Y Mosesson K Shtiegman M Katz Y Zwang G Vereb J Szollosi, J Biol Chem 278 24 21323 6 2003 Jun 13 10.1074/jbc.C300096200 12719435
40. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. HA van der AM de Vries-Smits AB Brenkman MH van Triest BN van den F Colland, Nat Cell Biol 8 10 1064 73 2006 Oct 10.1038/ncb1469 16964248
41. Structure of 20S proteasome from yeast at 2.4 A resolution. M Groll L Ditzel J Lowe D Stock M Bochtler HD Bartunik, Nature 386 6624 463 71 1997 Apr 3 10.1038/386463a0 9087403
42. Identification, purification, and characterization of a PA700-dependent activator of the proteasome. GN DeMartino RJ Proske CR Moomaw AA Strong X Song H Hisamatsu, J Biol Chem 271 6 3112 8 1996 Feb 9 8621709
43. Regulatory subunit interactions of the 26S proteasome, a complex problem. K Ferrell CR Wilkinson W Dubiel C Gordon, Trends Biochem Sci 25 2 83 8 2000 Feb 10.1016/S0968-0004(99)01529-7 10664589
44. AAA+: A class of chaperone-like ATPases associated with the assembly, operation, and disassembly of protein complexes. AF Neuwald L Aravind JL Spouge EV Koonin, Genome Res 9 1 27 43 1999 Jan 9927482
45. The multicatalytic proteinase. Multiple proteolytic activities. AJ Rivett, J Biol Chem 264 21 12215 9 1989 Jul 25 2745438
46. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. W Heinemeyer M Fischer T Krimmer U Stachon DH Wolf, J Biol Chem 272 40 25200 9 1997 Oct 3 10.1074/jbc.272.40.25200 9312134
47. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. M Groll W Heinemeyer S Jager T Ullrich M Bochtler DH Wolf, Proc Natl Acad Sci U S A 96 20 10976 83 1999 Sep 28 10500111 10.1073/pnas.96.20.10976
48. Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells. RC Gardner SJ Assinder G Christie GG Mason R Markwell H Wadsworth, Biochem J 346 Pt 2 447 54 2000 Mar 1 10677365
49. Range of sizes of peptide products generated during degradation of different proteins by archaeal proteasomes. AF Kisselev TN Akopian AL Goldberg, J Biol Chem 273 4 1982 9 1998 Jan 23 10.1074/jbc.273.4.1982 9442034
50. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. AF Kisselev TN Akopian KM Woo AL Goldberg, J Biol Chem 274 6 3363 71 1999 Feb 5 10.1074/jbc.274.6.3363 9920878
51. The comparative proteomics of ubiquitination in mouse. CA Semple, Genome Res 13 6B 1389 94 2003 Jun 12819137
52. Drug discovery in the ubiquitin regulatory pathway. BR Wong F Parlati K Qu S Demo T Pray J Huang, Drug Discov Today 8 16 746 54 2003 Aug 15 10.1016/S1359-6446(03)02780-6 12944097
53. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. A Kibel O Iliopoulos JA DeCaprio WG Kaelin Jr, Science 269 5229 1444 6 1995 Sep 8 10.1126/science.7660130 7660130
54. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. A Pause S Lee RA Worrell DY Chen WH Burgess WM Linehan, Proc Natl Acad Sci U S A 94 6 2156 61 1997 Mar 18 9122164 10.1073/pnas.94.6.2156
55. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. T Kamura DM Koepp MN Conrad D Skowyra RJ Moreland O Iliopoulos, Science 284 5414 657 61 1999 Apr 23 10.1126/science.284.5414.657 10213691
56. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. CE Stebbins WG Kaelin Jr NP Pavletich, Science 284 5413 455 61 1999 Apr 16 10.1126/science.284.5413.455 10205047
57. Targeting HIF-1 for cancer therapy. GL Semenza, Nat Rev Cancer 3 10 721 32 2003 Oct 10.1038/nrc1187 13130303
58. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. P Jaakkola DR Mole YM Tian MI Wilson J Gielbert SJ Gaskell, Science 292 5516 468 72 2001 Apr 20 11292861
59. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. WC Hon MI Wilson K Harlos TD Claridge CJ Schofield CW Pugh, Nature 417 6892 975 8 2002 Jun 27 10.1038/nature00767 12050673
60. A conserved family of prolyl-4-hydroxylases that modify HIF. RK Bruick SL McKnight, Science 294 5545 1337 40 2001 Nov 9 10.1126/science.1066373 11598268
61. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. E Berra E Benizri A Ginouves V Volmat D Roux J Pouyssegur, EMBO J 22 16 4082 90 2003 Aug 15 12912907 10.1093/emboj/cdg392
62. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. M Ohh CW Park M Ivan MA Hoffman TY Kim LE Huang, Nat Cell Biol 2 7 423 7 2000 Jul 10878807
63. Genotype-phenotype correlations in von Hippel-Lindau disease. KR Ong ER Woodward P Killick C Lim F Macdonald ER Maher, Hum Mutat 2006 Oct 5 17024664
64. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. P Carmeliet Y Dor JM Herbert D Fukumura K Brusselmans M Dewerchin, Nature 394 6692 485 90 1998 Jul 30 10.1038/28867 9697772
65. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. PH Maxwell GU Dachs JM Gleadle LG Nicholls AL Harris IJ Stratford, Proc Natl Acad Sci U S A 94 15 8104 9 1997 Jul 22 9223322 10.1073/pnas.94.15.8104
66. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. HE Ryan M Poloni W McNulty D Elson M Gassmann JM Arbeit, Cancer Res 60 15 4010 5 2000 Aug 1 10945599
67. Drosophila von Hippel-Lindau tumor suppressor complex possesses E3 ubiquitin ligase activity. T Aso K Yamazaki T Aigaki S Kitajima, Biochem Biophys Res Commun 276 1 355 61 2000 Sep 16 10.1006/bbrc.2000.3451 11006129
68. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. AC Epstein JM Gleadle LA McNeill KS Hewitson J O'Rourke DR Mole, Cell 107 1 43 54 2001 Oct 5 10.1016/S0092-8674(01) 00507-4 11595184
69. Tumour suppression by the human von Hippel-Lindau gene product. O Iliopoulos A Kibel S Gray WG Kaelin Jr, Nat Med 1 8 822 6 1995 Aug 10.1038/nm0895-822 7585187
70. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. JR Gnarra JM Ward FD Porter JR Wagner DE Devor A Grinberg, Proc Natl Acad Sci U S A 94 17 9102 7 1997 Aug 19 9256442 10.1073/pnas.94.17. 9102
71. Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice. E Kleymenova JI Everitt L Pluta M Portis JR Gnarra CL Walker, Carcinogenesis 25 3 309 15 2004 Mar 10.1093/carcin/bgh017 14604887
72. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. JB Brugarolas F Vazquez A Reddy WR Sellers WG Kaelin Jr, Cancer Cell 4 2 147 58 2003 Aug 10.1016/S1535-6108(03)00187-9 12957289
73. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. JR Gnarra S Zhou MJ Merrill JR Wagner A Krumm E Papavassiliou, Proc Natl Acad Sci U S A 93 20 10589 94 1996 Oct 1 8855222 10.1073/pnas.93.20.10589
74. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. A Schoenfeld EJ Davidowitz RD Burk, Proc Natl Acad Sci U S A 95 15 8817 22 1998 Jul 21 9671762 10.1073/pnas.95.15.8817
75. Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs of nude mice. S Naito AC von Eschenbach IJ Fidler, J Natl Cancer Inst 78 2 377 85 1987 Feb 3468299
76. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. K Kondo J Klco E Nakamura M Lechpammer WG Kaelin Jr, Cancer Cell 1 3 237 46 2002 Apr 10.1016/S1535-6108(02)00043-0 12086860
77. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. DB Mendel AD Laird X Xin SG Louie JG Christensen G Li, Clin Cancer Res 9 1 327 37 2003 Jan 12538485
78. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. TJ Abrams LB Lee LJ Murray NK Pryer JM Cherrington, Mol Cancer Ther 2 5 471 8 2003 May 12748309
79. Molecularly targeted therapy in renal cell carcinoma. WK Rathmell TM Wright BI Rini, Expert Rev Anticancer Ther 5 6 1031 40 2005 Dec 10.1586/14737140.5.6.1031 16336094
80. The proteasome as a target for cancer therapy. PM Voorhees EC Dees B O'Neil RZ Orlowski, Clin Cancer Res 9 17 6316 25 2003 Dec 15 14695130
81. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EB Traenckner S Wilk PA Baeuerle, EMBO J 13 22 5433 41 1994 Nov 15 7957109
82. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. M Groll CR Berkers HL Ploegh H Ovaa, Structure 14 3 451 6 2006 Mar 10.1016/j.str.2005.11.019 16531229
83. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. RC Kane AT Farrell R Sridhara R Pazdur, Clin Cancer Res 12 10 2955 60 2006 May 15 10.1158/1078-0432.CCR-06-0170 16707588
84. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. J An Y Sun M Fisher MB Rettig, Mol Cancer Ther 3 6 727 36 2004 Jun 15210859
85. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. GV Kondagunta B Drucker L Schwartz J Bacik S Marion P Russo, J Clin Oncol 22 18 3720 5 2004 Sep 15 10.1200/JCO.2004.10.155 15365068
86. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. NB Davis DA Taber RH Ansari CW Ryan C George EE Vokes, J Clin Oncol 22 1 115 9 2004 Jan 1 10.1200/JCO.2004.07.165 14701773
87. The proteasome and proteasome inhibitors in cancer therapy. PM Voorhees RZ Orlowski, Annu Rev Pharmacol Toxicol 2006 46 189 213 10.1146/annurev. pharmtox.46.120604.141300 16402903
88. P53 and prognosis: new insights and further complexity. KH Vousden C Prives, Cell 120 1 7 10 2005 Jan 14 15652475
89. Drug discovery in the ubiquitin-proteasome system. G Nalepa M Rolfe JW Harper, Nat Rev Drug Discov 5 7 596 613 2006 Jul 10.1038/nrd2056 16816840
90. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. LT Vassilev BT Vu B Graves D Carvajal F Podlaski Z Filipovic, Science 303 5659 844 8 2004 Feb 6 10.1126/science.1092472 14704432
91. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Y Yang RL Ludwig JP Jensen SA Pierre MV Medaglia IV Davydov, Cancer Cell 7 6 547 59 2005 Jun 10.1016/j.ccr.2005.04.029 15950904
92. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. M Gorospe JM Egan B Zbar M Lerman L Geil I Kuzmin, Mol Cell Biol 19 2 1289 300 1999 Feb 9891063
93. HSP90 and the chaperoning of cancer. L Whitesell SL Lindquist, Nat Rev Cancer 5 10 761 72 2005 Oct 10.1038/nrc1716 16175177
94. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. WG An TW Schulte LM Neckers, Cell Growth Differ 11 7 355 60 2000 Jul 10939589
95. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. C Chavany E Mimnaugh P Miller R Bitton P Nguyen J Trepel, J Biol Chem 271 9 4974 7 1996 Mar 1 8617772
96. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. EG Mimnaugh C Chavany L Neckers, J Biol Chem 271 37 22796 801 1996 Sep 13 8798456
97. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. DB Solit FF Zheng M Drobnjak PN Munster B Higgins D Verbel, Clin Cancer Res 8 5 986 93 2002 May 12006510
98. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. E Minet D Mottet G Michel I Roland M Raes J Remacle, FEBS Lett 460 2 251 6 1999 Oct 29 10.1016/S0014-5793(99)01359-9 10544245
99. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. JS Isaacs YJ Jung EG Mimnaugh A Martinez F Cuttitta LM Neckers, J Biol Chem 277 33 29936 44 2002 Aug 16 10.1074/jbc.M204733200 12052835
100. Heat shock protein 90 as a molecular target for cancer therapeutics. JS Isaacs W Xu L Neckers, Cancer Cell 3 3 213 7 2003 Mar 10.1016/S1535-6108(03) 00029-1 12676580
101. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. H Zhong K Chiles D Feldser E Laughner C Hanrahan MM Georgescu, Cancer Res 60 6 1541 5 2000 Mar 15 10749120
102. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. R Fukuda K Hirota F Fan YD Jung LM Ellis GL Semenza, J Biol Chem 277 41 38205 11 2002 Oct 11 10.1074/jbc.M203781200 12149254
103. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. CC Hudson M Liu GG Chiang DM Otterness DC Loomis F Kaper, Mol Cell Biol 22 20 7004 14 2002 Oct 12242281 10.1128/MCB.22.20.7004-7014.2002
104. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. MB Atkins M Hidalgo WM Stadler TF Logan JP Dutcher GR Hudes, J Clin Oncol 22 5 909 18 2004 Mar 1 10.1200/JCO.2004.08.185 14990647
105. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. GV Thomas C Tran IK Mellinghoff DS Welsbie E Chan B Fueger, Nat Med 12 1 122 7 2006 Jan 10.1038/nm1337 16341243
106. Ubiquitin pathway in VHL cancer syndrome. M Ohh, Neoplasia 8 8 623 9 2006 Aug 16925945 10.1593/neo.06442